Mogi C et al. |
Sphingosylphosphorylcholine antagonizes proton-sensing ovarian cancer G-protein-coupled receptor 1 (OGR1)-mediated inositol phosphate production and cAMP accumulation. |
2005 |
J. Pharmacol. Sci. |
pmid:16210776
|
Nozawa M et al. |
Novel procedure for measuring psychosine derivatives by an HPLC method. |
1992 |
J. Neurochem. |
pmid:1629732
|
Imokawa G |
A possible mechanism underlying the ceramide deficiency in atopic dermatitis: expression of a deacylase enzyme that cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. |
2009 |
J. Dermatol. Sci. |
pmid:19443184
|
Sun Y et al. |
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. |
2010 |
Hum. Mol. Genet. |
pmid:20047948
|
Auray-Blais C et al. |
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? |
2010 |
Clin. Chim. Acta |
pmid:20716442
|
Li YT et al. |
Selective extraction and effective separation of galactosylsphingosine (psychosine) and glucosylsphingosine from other glycosphingolipids in pathological tissue samples. |
2011 |
Neurochem. Res. |
pmid:21136152
|
Xu YH et al. |
Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. |
2011 |
Mol. Genet. Metab. |
pmid:21257328
|
Dekker N et al. |
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. |
2011 |
Blood |
pmid:21868580
|
Sun Y et al. |
Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. |
2012 |
J. Biol. Chem. |
pmid:22167193
|
Zhang CK et al. |
Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. |
2012 |
Am. J. Hematol. |
pmid:22388998
|
Cabrera-Salazar MA et al. |
Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. |
2012 |
PLoS ONE |
pmid:22912851
|
Sardi SP et al. |
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. |
2013 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:23297226
|
Sun Y et al. |
Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease. |
2013 |
PLoS ONE |
pmid:23520473
|
Pavlova EV et al. |
B cell lymphoma and myeloma in murine Gaucher's disease. |
2013 |
J. Pathol. |
pmid:23775597
|
Gaspar P et al. |
Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis. |
2014 |
J. Lipid Res. |
pmid:24212238
|
Rolfs A et al. |
Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. |
2013 |
PLoS ONE |
pmid:24278166
|
Angka L et al. |
Glucopsychosine increases cytosolic calcium to induce calpain-mediated apoptosis of acute myeloid leukemia cells. |
2014 |
Cancer Lett. |
pmid:24631520
|
Aflaki E et al. |
Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. |
2014 |
Sci Transl Med |
pmid:24920659
|
Gopalan V et al. |
Kinetic analysis of the interaction of alkyl glycosides with two human beta-glucosidases. |
1989 |
Biochem. J. |
pmid:2508630
|
Burrow TA et al. |
CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. |
2015 |
Mol. Genet. Metab. |
pmid:25219293
|